The total gross expenditure by major companies on R&D across the Asia Pacific region crossed the $15 billion mark (approx) in 2022. Oncology, neurology, and immunology continue to draw a significant chunk of this investment. With Asia’s growing importance in R&D, the region is poised to play a significant role in shaping the future of pharmaceutical innovation globally.
According to Pharmaprojects, as of January 2022, the top four countries in the region with the most drugs in their pipelines are China, South Korea, Japan and Australia. China leads with 20.8 per cent of the global pipeline, representing 4,189 drugs. South Korea follows closely behind with 13.1 per cent of the pipeline or 2,627 drugs. Japan and Australia have around 10 per cent of the pipeline, with 1,931 and 2,010 drugs, respectively. These four countries demonstrate a strong focus on research and development in the pharmaceutical industry, and their contributions to drug development and innovation are likely to have a significant impact on the future of healthcare.
2022 was a crucial year for many countries as many R&D projects which were halted during the COVID-19-induced slowdown resumed. The region saw an increase in immuno-oncology drugs and many of the top companies expanded their manufacturing footprint with the expansion of new facilities. The average R&D investment was 6-10 per cent of the revenue.
We have featured the top-performing publicly listed companies with more than a billion in revenue from developed markets such as China, Australia, Japan and South Korea. As for Taiwan and Indonesia, we have covered the largest companies in their country.
CSL (Australia)
This story is from the May 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the May 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
